COVID ARDS Trial Topline 60-Day Results
Filed with ASX · · 3 pages · English
Melbourne, Australia; April 30 and New York, USA; April 29, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the 60 day results from the randomized controlled trial of remestemcel-L in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) which had been halt
Earlier from Mesoblast
- Mesoblast Raises US$110M Led By US Strategic Investor Group
- Mesoblast Phase 3 Chronic Low Back Pain Results
- Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
- Mesoblast Update on COVID-19 ARDS Trial
- Trading halt
Later from Mesoblast
- MSB Reports Q3 Financial Results and Operational Highlight
- Mesoblast Update on Chronic Low Back Pain Program
- MSB Annual Financial Results and Operational Progress
- AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
- MSB and Oaktree Conclude Refinancing of Senior Debt Facility
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast